Despite growing adoption of CAR-T therapy in large B-cell lymphoma (LBCL), new findings from Spherix Global Insights suggest that operational and logistical barriers continue to impact real-world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results